Lupin Ltd submitted an original Abbreviated New Drug Application (ANDA) identified as ANDA216716 to the U.S. Food and Drug Administration. The submission is recorded under a standard review priority and is classified as an original submission (submission number 1). The FDA status for this application is listed as "TA" (Tentative Approval) with the status date of August 13, 2024. No additional details about the product or approval timeline were provided in the source data.
規制動向2026年9月18日•3分で読めます
Lupin Ltd Submits Original ANDA216716 to FDA – Tentative Approval
Lupin Ltd filed an original ANDA (application number ANDA216716) with the FDA, currently listed as Tentative Approval as of August 13, 2024.
Pharmacountryチームがまとめました · 出典： FDA.gov
トピック：
評価
(0)
(0)
(0)
(0)
(0)
評価を残す